About AAPP Toolkits
AAPP toolkits highlight both the evidence base available as well as strategies of clinical decision making used by expert psychiatric pharmacist clinicians. The content reflects the views and practice of the authors as substantiated with evidence-based facts as well as opinion and experience. Toolkits are peer reviewed by psychiatric pharmacists. Authors and AAPP review and update toolkits annually and strive to use up-to-date, non-stigmatizing language. Terminology does evolve rapidly and often regionally such that there may be differences between reader experiences and expectations and those of the author(s). AAPP members receive complimentary, continuous access to toolkits. Non-members can purchase for a fee for a period of 3 months.
Buprenorphine and methadone are first-line pharmacotherapy options for the treatment of opioid use disorder (OUD). Despite their importance, confusion remains regarding their use in acute care settings, especially when patients seek care at institutions that do not have opioid treatment program (OTP) licensure. This toolkit addresses frequently asked questions regarding the use of buprenorphine and methadone in acute care settings.